OncoSec Medical Poised for Exciting 2014

<p style="text-align: center;"><img loading="lazy" class="aligncenter size-full wp-image-273724" alt="" src="https://www.cheatsheet.com/wp-content/uploads/2012/09/Vaccine-Syringe-Needle.jpg" width="640" height="480" srcset="https://www.cheatsheet.com/wp-content/uploads/2012/09/Vaccine-Syringe-Needle.jpg 640w, https://www.cheatsheet.com/wp-content/uploads/2012/09/Vaccine-Syringe-Needle.jpg?w=80&h=60 80w, https://www.cheatsheet.com/wp-content/uploads/2012/09/Vaccine-Syringe-Needle.jpg?w=150&h=113 150w" sizes="(max-width: 640px) 100vw, 640px" /></p> <p>Investors looking for an interesting opportunity in biotechnology may want to consider <b>OncoSec Medical </b>(ONCS.PK). Shares of OncoSec Medical have exploded by 40 percent over the past month as investors try to grab shares before things start to heat up in 2014.</p> <p>OncoSec Medical is a development-stage biotechnology company that is developing treatments for advanced-stage skin cancer. The company focuses on three types of skin cancer: melanoma, cutaneous T-cell lymphoma, and Merkel cell lymphoma. The company’s platform revolves around the theory of immunotherapy. The basic idea of immunotherapy is to embrace the power of using a person’s immune system to help eradicate a disease.</p> <p>I would argue that immunotherapy has been the theme of 2013, as several companies have seen enormous gains because of its potential. One such company is <b>Celldex Therapeutics </b>(NASDAQ:CLDX). Shares of Celldex are up about 250 percent over the past 52 weeks. Celldex has shown great promise with its deep pipeline, including a couple of candidates that have the potential to offer breakthrough treatments for breast and brain cancer, among others.</p> <p>Immunotherapy is also catching the attention of major banks such as <a rel="noopener" href="http://www.reuters.com/article/2013/05/31/us-cancer-immunotherapy-idUSBRE94U05P20130531" target="_blank">Citigroup</a>. Citigroup research analyst Andrew Baum expects immunotherapies to make up the majority of treatments for up to 60 percent of cancers over the next 10 years. Currently, immunotherapies only comprise 3 percent of cancer treatments. Baum expects that the rise in immunotherapy use will create an annual market size of $35 billion. With that potential, it is hard not to like a company like OncoSec Medical, currently valued at just $75 million.</p>